1. Back E.E., Henning K.J., Kallenbach L.R., Briz K.A., Gunn R.A., and Melius J.M., 1993, Risk factors for developing eosinophilia-myalgia syndrome among L-tryptophan users in New York. J Rheumatol20: 666
2. Belongia E.A., Hedberg C.W., Gleich G.J., White K.E., Mayeno A.N., Loegering D.A., Diennetti S.L., Pirie P.L., and MacDonald K.L., and Osterholm M.T., 1990, An investigation of the cause of the eosino-philia-myalgia syndrome associated with tryptophan use. N Engl J Med323: 357
3. Belongia E.A., Mayeno A.N., and Osterholm M.T., 1992, The eosinophilia-myalgia syndrome and tryptophan. Annu Rev Nutr12: 235
4. Buss W.C., Bankhurst A.D., Stephanek J., Pastussn A., and Mayen A.N., 1995, The tryptophan contaminant EBT associated with eosinophilia-myalgia syndrome is an amino acid analog. FASEB J9: A1028
5. Cahard D., Canat X., Carayon P., Rogue C., Casella P., and LeFur G., 1994, Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab. Invest70: 23